Clomiphene in Males With Prolactinomas and Persistent Hypogonadism

This study has been completed.
Information provided by:
Federal University of São Paulo Identifier:
First received: June 12, 2008
Last updated: June 13, 2008
Last verified: June 2008
Prolactinomas are usually associated with hypogonadotropic hypogonadism in both sexes. Clomiphene citrate is a well known selective estrogen receptor modulator that increases gonadotropin secretion via hypothalamic-pituitary action. We conducted a prospective, open label clinical trial of CC to evaluate its effects in reverting persistent HH in male patients with prolactinomas under dopaminergic agonist treatment.

Condition Intervention Phase
Hypogonadotropic Hypogonadism
Drug: Clomiphene citrate
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Official Title: Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism

Resource links provided by NLM:

Further study details as provided by Federal University of São Paulo:

Primary Outcome Measures:
  • assess the effects of CC treatment on testosterone levels in male patients with prolactinomas and persistent HH on dopaminergic agonist therapy [ Time Frame: 10 days, 4, 8 and 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Assess the effects of CC on sexual function, fertility, body composition, lipid and glucose metabolism, and quality of life were also evaluated.

Enrollment: 15
Study Start Date: June 2004
Study Completion Date: June 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Clomiphene
Clomiphene 50 mg/day for 12 weeks
Drug: Clomiphene citrate
Clomiphene 50 mg/day for 12 weeks


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • a minimum follow-up of 6 months under DA therapy with normal serum prolactin or with maximum DA dose (3.5 mg/week of cabergoline or 10 mg/day of bromocriptine for at least 2 months)
  • serum total testosterone less than 300ng/dl with normal or low LH and FSH levels after discontinuing testosterone replacement for at least 2 months.

Exclusion Criteria:

  • impossibility to attend scheduled visits and irregular compliance to DA treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00697814

Neuroendocrine Unit - Escola Paulista de Medicina (UNIFESP)
Sao Paulo, SP, Brazil, 09541-330
Sponsors and Collaborators
Federal University of São Paulo
Study Chair: Julio Abucham, MD, PhD Neuroendocrine Unit
  More Information

Responsible Party: Julio Abucham, Neuroendocrine Unit Identifier: NCT00697814     History of Changes
Other Study ID Numbers: 1374/04 
Study First Received: June 12, 2008
Last Updated: June 13, 2008
Health Authority: Brazil: National Committee of Ethics in Research
Brazil: Ministry of Health

Keywords provided by Federal University of São Paulo:
Hypogonadotropic hypogonadism

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Gonadal Disorders
Hypothalamic Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Nervous System Diseases
Pituitary Diseases
Pituitary Neoplasms
Estrogen Antagonists
Estrogen Receptor Modulators
Fertility Agents
Fertility Agents, Female
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Therapeutic Uses processed this record on April 27, 2016